SBH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sally Beauty Holdings Inc (SBH) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has some positive catalysts, the technical indicators and financial performance suggest caution. The stock's recent price trend is bearish, and the financials show declining net income and EPS, which are critical for long-term growth. Analysts' ratings are mixed, and there is no strong trading sentiment or proprietary trading signal to support an immediate buy decision.
The stock is in a bearish trend with MACD negatively expanding and RSI at 25.927, indicating oversold conditions but not a clear buy signal. The current price of $14.75 is near the S1 support level of $14.863, with further downside risk to S2 at $14.33. Moving averages are converging, showing no clear trend reversal.
Analysts like TD Cowen and Canaccord have raised price targets to $20, citing durable margins and growth-driving initiatives.
Expansion of the Rooted in Success campaign to HBCUs could enhance brand influence among younger consumers.
Gross margin increased to 51.24%, up 0.79% YoY, showing operational efficiency.
Net income dropped by -25.33% YoY, and EPS declined by -22.41% YoY in Q1 2026, indicating weakening profitability.
Morgan Stanley maintains an Underweight rating, citing limited medium-term EBIT growth.
The stock price is down -3.05% in the regular market, reflecting negative sentiment.
In Q1 2026, revenue increased slightly by 0.56% YoY to $943.17M. However, net income dropped significantly by -25.33% YoY to $45.56M, and EPS declined by -22.41% YoY to $0.45. Gross margin improved marginally to 51.24%, up 0.79% YoY, but the overall financial performance indicates challenges in profitability.
Analysts are mixed on SBH. TD Cowen and Canaccord have Buy ratings with price targets of $20, citing growth-driving initiatives and durable margins. However, Morgan Stanley has an Underweight rating with a $16 target, citing limited medium-term EBIT growth. Raymond James upgraded the stock to Outperform with a $19 target, naming it a top Smid-cap value pick for 2026.
